Vistagen Therapeutics, Inc. — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 22/100
What the filing says
Vistagen filed an 8-K on 2026-10-30 disclosing Item 2.05 (Cost Associated with Exit or Disposal Activities) and Item 8.01 (Other Events). The filing header provides no concrete dollar amounts, share counts, counterparty names, percentages, or dates beyond the filing date (2026-10-30) and report date (2026-10-26). The actual content of the costs and any associated activities cannot be determined from the metadata provided.
Why this rating
No financial data disclosed in header; cannot assess materiality. Routine 8-K filing structure suggests moderate event but magnitude unknown. Requires full document review.
Extracted items
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.